Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Formulary Will Have More Than VA’s 30 Classes

Executive Summary

The Medicare Part D model formulary will have more than the 30 therapeutic drug classes included in the Veterans Affairs formulary, Centers for Medicare & Medicaid Services Administrator Mark McClellan said at a National Health Council Medicare briefing in Washington, D.C. July 15

You may also be interested in...



COX-2s May Be Grouped With NSAIDs In Model Medicare Formulary

COX-2 inhibitors may be included as part of the broader NSAID category in the model Medicare formulary under development by the U.S. Pharmacopeia

COX-2s May Be Grouped With NSAIDs In Model Medicare Formulary

COX-2 inhibitors may be included as part of the broader NSAID category in the model Medicare formulary under development by the U.S. Pharmacopeia

“Prior Authorization Assistance” May Be New Tool Under Medicare Rx

Drug manufacturers may want to consider establishing prior authorization assistance programs to prepare for life under Medicare formularies, Parexel Health Policy & Payer Relations Senior Project Manager Tom Snyder said

Related Content

Topics

UsernamePublicRestriction

Register

PS044359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel